2024年11月19日 · •Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer.•MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.•Mitigation strategies to prevent treatment disruption have historically relied on corticosteroid ...

2024年12月1日 · Mirvetuximab soravtansine (MIRV) is used in the treatment of FRα positive, platinum-resistant epithelial ovarian cancer. MIRV is associated with ocular events, leading to dose delays, dose reductions, and discontinuations of chemotherapy.

mirv是一种以叶酸受体-α(frα)为靶点的新型抗体-药物偶联物。mirv按照adc类药物设计，由特异性frα结合抗体，可裂解的连接子和细胞毒性药物dm4构成，当mirv作用后引起卵巢癌细胞周期停滞及凋亡。 mirv结构

The safety of mirvetuximab soravtansine-gynx (MIRV) was analyzed in 682 patients with recurrent ovarian cancer. Low-grade gastrointestinal, fatigue, headache, peripheral neuropathy, and resolvable ocular adverse events were common.

2024年11月29日 · MIRV is a Food and Drug Administration-approved FRα-targeting antibody–drug conjugate. MIRV was assessed as ≥3L treatment for FRα-positive PSOC in the phase II PICCOLO trial. MIRV was efficacious in ORR …

Mirvetuximab Soravtansine (MIRV) is a promising antibody‒drug conjugate (ADC) that targets folate receptor alpha (FRα), which is overexpressed in several types of solid tumors. In November 2022, MIRV was approved in the USA for the treatment of ...

Mirvetuximab soravtansine (MIRV) is the first biomarker-driven therapy for patients with platinum-resistant ovarian cancer. This antibody-drug conjugate binds folate receptor alpha, overexpressed by most ovarian cancers (limited in normal tissue).

A multiple independently targetable reentry vehicle (MIRV) is an exoatmospheric ballistic missile payload containing several warheads, each capable of being aimed to hit a different target. The concept is almost invariably associated with intercontinental ballistic missiles carrying thermonuclear warheads , even if not strictly being limited to ...

2024年12月27日 · Background: Mirvetuximab Soravtansine (MIRV) is a promising antibody‒drug conjugate (ADC) that targets folate receptor alpha (FRα), which is overexpressed in several types of solid tumors. In November 2022, MIRV was approved in the USA for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian ...

2023年7月12日 · mirv通过可裂解连接子技术，连接人源化frα单抗和微管抑制剂美登素衍生物dm4。 药物在外周循环系统中保持稳定，并在进入肿瘤细胞后裂解释放毒素，通过抑制微管蛋白聚合和组装阻碍肿瘤细胞的有丝分裂，最终导致细胞周期停滞和死亡。